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Abstract
Fluticasone propionate – the first carbothioate corticoste-
roid – has been classified as a potent anti-inflammatory
drug for dermatological use. It is available as 0.05%
cream and 0.005% ointment formulations for the acute
and maintenance treatment of patients with dermatolog-
ical disorders such as atopic dermatitis, psoriasis and
vitiligo. This glucocorticoid is characterized by high lipo-
philicity, high glucocorticoid receptor binding and activa-
tion, and a rapid metabolic turnover in skin. Although
skin blanching following fluticasone propionate exceeds
that of corticosteroids of medium strength, several clini-
cal trials demonstrate a low potential for cutaneous and
systemic side-effects, even in difficult-to-treat areas like
the face, the eyelids and intertriginous areas. Even
among paediatric patients with atopic dermatitis, flutica-
sone propionate proved to be safe and effective. These
pharmacological and clinical properties are reflected by
the high therapeutic index of this glucocorticoid.
Copyright © 2005 S. Karger AG, Basel
Introduction
Topical glucocorticoids are the drugs most often pre-
scribed by dermatologists due to their anti-inflammatory,
immunosuppressive and antiproliferative effects, which
are thought to be their primary mechanism of action in
the treatment of several skin disorders [1]. The clinical
use of these drugs, however, is still restricted by the poten-
tial for adverse events. Therefore recent research has
focused on the development of steroids with lower toxici-
ty without a loss of effectiveness. The synthetic carbo-
thioate corticosteroid fluticasone propionate (FP, Fluti-
vate®) combines excellent clinical efficacy with minimal
risk for local or systemic adverse events. It is available as a
cream and ointment with similar potency, yet differing
strength (0.05 vs. 0.005%) of the active agent. This article
reviews the pharmacology and the safety profile as well as
the use of topical FP in clinical practice, paying particular
attention to the treatment and prophylaxis of skin dis-
eases such as atopic dermatitis (AD), psoriasis and
vitiligo.
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Fig. 1. Molecular structure of cortisol, FP
and its inactive metabolite. Structural modi-
fications at positions 1, 6 and 9 are activat-
ing in terms of anti-inflammatory and min-
eralocorticoid activity, while the two esterifi-
cations highly increase the natural lipophil-
icity and the drug uptake of FP. Rapid meta-
bolization to the inactive moiety due to ester
cleavage replacing the thioester moiety at
position 17 by a carboxylic acid function
contributes to the low systemic activity.
Chemical Structure and Glucocorticoid
Receptor Affinity
In general, glucocorticoids have a so-called androstane
structure with 17 carbon atoms arranged in three 6-mem-
bered rings and one 5-membered ring. Additional modifi-
cations to this basic skeletal structure have led to the
development of highly lipophilic corticosteroids such as
FP, which has been classified as a potent corticosteroid
[2]. In this fluoromethyl androstane-17ß-carbothioate, an
extra double bond at positions 1 and 2, two fluorines at
positions 6 and 9, and an ·-methyl group at position 16
are additionally inserted (fig. 1). The two esterifications at
position 17 (with a propionate group) and at position 20
(with a fluorized thio ester, named ‘carbothioate’) highly
increase the molecule’s natural lipophilicity, its cutaneous
drug uptake and its binding to human skin tissue [3] as
well as to the glucocorticoid receptor (GR), a 777-amino-
acid protein member of the superfamily of ligand-recep-
tor nuclear receptors [4]. X-ray crystallographic investiga-
tions revealed that the carbonyl of the 17ß-carbothioate
ester substituent lies below the plane of ring D rather than
above, as observed for other corticosteroids, and might
explain the rapid enzymatic hydrolysis of FP to its inac-
tive metabolite [5].
Quantitative structure-activity relationship studies in-
dicate that FP has a high affinity to the GR reflected by a
fast association and slow dissociation rate, suggesting that
the FP-GR complex will be stable [6]. Indeed, using a
kinetic assay, Högger and Rohdewald [7] measured the
GR equilibrium dissociation constant of FP in human
lung cytosol and reported a value of 0.49 nmol/l. The
receptor complex half-life exceeded 10 h, which signifi-
cantly differs from dexamethasone (1 h), triamcinolone
acetonide (4 h) and budesonide (5 h) [7]. Normalization
of the relative receptor affinity to dexamethasone, with
dexamethasone given a value of 100, resulted in a remark-
able value of 1,910 for FP. Results of an equilibrium com-
petition assay (relative receptor affinity: 1,401) are rather
close [7]. Despite these receptor pharmacokinetic differ-
ences, FP provides selectivity for the GR by having only
little or no affinity to progestagen, androgen, oestrogen or
mineralocorticoid receptors [8]. This GR affinity can be
attributed to the halogenation at the 9· position increas-
ing both glucocorticoid and mineralocorticoid effects,
presumably through an electron-withdrawing effect of the
11ß-hydroxyl group [9]. Furthermore, the insertion of an
·-methyl substituent at position 16 is known to eliminate
mineralocorticoid activity [8].
Effects of the FP-GR Complex
GR gene regulations have been studied at the molecu-
lar level. Upon interaction with the GR, FP interferes
with the effects of transcription factors such as the activat-
ing protein (AP) 1 and the nuclear factor ÎB [10], which
are involved in the activation of pro-inflammatory cyto-
Safety and Efficacy of Fluticasone
Propionate
Skin Pharmacol Physiol 2005;18:3–11 5
kines like interleukin (IL) 1· and IL-1ß [11]. For example,
AP-1-induced transactivation increases rapidly in re-
sponse to mitogenic factors and tumour promoters and
enhances cell proliferation and activates inflammatory
signalling pathways. Like the other corticosteroids, FP
potently antagonizes AP-1 effects. Inhibition of AP-1 and
nuclear factor ÎB explains anti-inflammatory, immuno-
suppressive and antimitotic glucocorticoid effects in the
treatment of psoriasis or eczema [11]. Genes known to be
up-regulated by FP include those encoding for lipocortin I
and the p11/calpactin-binding protein which are involved
in the suppression of the release of arachidonic acid [11].
Furthermore, lipocortin I inhibits phospholipase A2, re-
ducing the amount of arachidonic acid released from
phospholipids [1].
At the cellular level, the beneficial properties of FP in
terms of inflammation and pathogenic hyperproliferation
also become obvious from the decrease in markers of
inflammation in human endothelial cells, such as the
endothelial-leukocyte adhesion molecule and the vascular
cell adhesion molecule [12, 13]. Furthermore, FP inhib-
its TNF-·-stimulated E-selectin at a concentration of
1 nmol/l in human endothelial cells, whereas 8-fold higher
concentrations of budesonide are required for the same
effect [12]. In vitro studies also indicate that FP directly
suppresses a continuous or excessive activation of neutro-
phil function and might suggest a further role for this
agent in the inhibition of inflammation and in the modu-
lation of neutrophil-mediated damage of the connective
tissue [14]. Furthermore, FP normalizes the increased lev-
el of mucosal mast cells in presensitized animals, reduces
T cell proliferation and enhances T cell apoptosis at least
partly by the inhibition of the T cell growth factor IL-2
[15]. In patients with bronchial asthma, FP reduces eosin-
ophilia by promoting eosinophil apoptosis [16] and indi-
rectly by a diminished production of cytokines such as
IL-5, IL-8, IL-13 and the respective receptors that are
involved in eosinophil maturation, recruitment and sur-
vival [15, 17, 18]. In the presence of IL-5, FP (EC50 =
1.7 nmol/l) was revealed to induce concentration-depen-
dent apoptosis of eosinophils being 5 times more potent
than budesonide and 10 times more potent than triamci-
nolone acetonide and flunisolide [19].
Vasoconstrictor Activity in Humans
When applied under occlusion to the normal skin of
human subjects, potent glucocorticoids produce blanch-
ing or vasoconstriction. In this standard test, a known
range of doses of the glucocorticoid is applied to the skin
of the inner forearm, and the blanching due to vasocon-
striction is compared visually to a laboratory standard,
e.g. fluocinolone acetonide [20]. The intensity of blanch-
ing is then quantified to estimate the topical activity of
corticosteroids. Subsequent studies have shown that vaso-
constrictor activity is closely related to anti-inflammatory
effects in skin diseases [21].
A series of vasoconstrictor studies were undertaken to
compare FP to topical corticosteroids used for inflamma-
tory diseases [22]. FP turned out to be 3 times more
potent than beclomethasone-17,21-dipropionate and its
active metabolite, beclomethasone-17-monopropionate,
and equipotent to mometasone furoate, a synthetic 16·-
methyl analogue of beclomethasone. FP was 10 times
more potent than triamcinolone acetonide, flunisolide
and fluocinolone acetonide, and intermediate in potency
between betamethasone-17-valerate (less potent) and clo-
betasol-17-propionate (more potent) [22].
Safety Profile
Most topical corticosteroids are absorbed in quantities
that can produce both systemic and topical adverse
events. These adverse effects are related mainly to actions
on electrolyte and water balance, neoglycogenesis and to
an inhibitory effect on adenohypophyseal function [23].
Potential for Systemic Adverse Events
The principal systemic side-effects of glucocorticoids
comprise Cushing’s syndrome, hypertension, electrolyte
imbalance, diabetes mellitus, pseudoprimary aldosteron-
ism, osteoporosis or growth retardation. FP is well tolerat-
ed having a low potential to cause adverse systemic
effects. Compared to first-generation topical corticoste-
roids such as betamethasone, the compound yields little
hypothalamic-pituitary-adrenal axis effects reflecting the
high quotient between topical activity and systemic activ-
ity due to its lipophilicity [24, 25] and its hepatic metabo-
lism to the inactive moiety 17ß-carboxylic acid [26, 27].
In a clinical trial investigating the propensity for systemic
absorption, 25 g FP 0.05% cream were allotted twice daily
under occlusion for 5 days in one group, and 12.5 g FP
0.05% cream were applied twice daily without occlusion
for 21 days in the other group. Even upon application of
these large doses there was no evidence of a suppressed
cortisol secretion underlining the low propensity for sys-
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temic absorption of FP [28]. In 120 patients with moder-
ate-to-severe eczema, the safety and tolerability of FP
0.05% cream versus hydrocortisone-17-butyrate 0.1%
cream was assessed for 3 months. After 3 months of treat-
ment, plasma cortisol levels were not significantly af-
fected by either agent. Among patients with changes in
plasma cortisol, 56% were in the hydrocortisone-17-buty-
rate group and 27% were in the FP group [29]. Although
the 9·-fluorination enhances all the biological activities of
glucocorticoids, a concomitant increase in adverse sys-
temic effects could not be reported [4].
Potential for Local Adverse Events
Moreover, topical steroids are as a rule capable of caus-
ing local side-effects such as skin atrophy, steroid face and
teleangiectasia, pruritus, burning, perioral dermatitis, ro-
sacea, corticoid acne, allergic contact dermatitis, hypertri-
chosis or hyperpigmentation [30].
Skin Atrophy
Skin atrophy as the most relevant local side-effect is
expressed by flattening of the Malphigian and horny
layers and of the rete ridges [31]. The decreased size of
keratinocytes and of the stratum corneum, the reduced
amount of melanin transferred to keratinocytes and a
diminished synthesis of collagen in particular largely con-
tribute to epidermal and dermal thinning, with resulting
teleangiectasia, ecchymoses and skin fragility [32].
In the previously mentioned trial in patients with ecze-
ma, none of the subjects treated with FP experienced any
major local side-effects, including cutaneous atrophy [29].
Only 8.5% of the persons treated with FP and 11.7% of
the hydrocortisone-17-butyrate group observed drug-re-
lated adverse events such as folliculitis and pustules. A
further randomized, placebo-controlled study with 40
healthy individuals used pulsed A scan ultrasound to
characterize the extent of cutaneous atrophy due to FP
0.05% cream versus vehicle cream after once daily non-
occlusive application for either 2, 4, 6 or 8 weeks. FP
caused a mean decrease in skin thickness by 3% com-
pared with placebo (p = 0.62) [33] while the dermal thin-
ning potential was 15–16% for betamethasone valerate
0.1% cream and for hydrocortisone-17-butyrate 0.01%
cream, and 13% for mild corticosteroids such as hydro-
cortisone 1.0% cream when applied twice daily [34]. The
low reduction seen with once daily applied FP 0.05%
cream points towards a minimal atrophogenic potential,
since once daily applied fluticasone 0.05% cream has
been shown to be equally effective with the twice daily
application [35]. Likewise, a paediatric safety trial enroll-
ing 51 children (aged 3 months to 5 years) with extensive
moderate to severe psoriasis or eczema revealed a low
skin thinning potential (2%) even after an extensive treat-
ment with large quantities of FP 0.05% cream [36].
Eyelid/Periorbital Dermatoses and Contact Allergy
Local side-effects might in particular occur after appli-
cation of topical steroids in the treatment of eyelid or
periorbital dermatoses (i.e. seborrhoeic dermatitis, con-
tact dermatitis and AD, lichen simplex and blepharitis) as
a frequent cause of conjunctival sac contamination, which
can lead to glaucoma, ocular hypertension, cataracts and
blindness. Recently, Tan et al. [37] have evaluated the in
vitro penetration of FP 0.005% ointment in samples of
normal human eyelid skin by means of modified diffusion
chambers and concluded that only small amounts of FP
0.005% ointment penetrate eyelid skin.
Topical corticosteroids have also been documented as
a frequent cause of true, delayed-type hypersensitivity
reactions leading to a disseminated or generalized ecze-
matous reaction [38]. They were found to be the seventh
most common allergen after nickel sulphate, cobalt chlo-
ride, colophony, fragrance mix, balsam of Peru and potas-
sium dichromate. Several problems are combined with
the identification of a contact allergy to corticosteroids:
the clinical picture is often misleading, the patch test pro-
cedure is a subject of discussion and the diagnosis is prob-
ably not considered often enough because clinicians were
rarely aware of such a possible adverse effect [39]. Con-
cerning treatment options, non-fluorinated corticoste-
roids might be more likely to induce a contact allergy than
fluorinated steroids since they react more rapidly with
arginine than fluorinated steroids, thus inducing sensiti-
zation [40]. Further studies point towards a low potential
of FP concerning hypersensitivity reactions and cross-
sensitivity reactions to non-fluorinated steroids, such as
tixocortol pivalate or budesonide [41]. In a recent patch
test study, the allergenic potential of FP 0.05% cream was
analysed both with patients who had used it to treat ecze-
ma as well as persons with a known contact allergy to oth-
er corticosteroids [42]. Of these 206 corticosteroid-allergic
subjects, 118 had actually used Flutivate, and 155 were
tested with an extended corticosteroid series (consisting
of 63 different corticosteroids) in which it was included.
As a result, only 3.3% (i.e. 7 persons) gave a clear (+ or ++)
reaction to it. Most notably, only 1 of these 7 FP-allergic
patients had actually been exposed to fluticasone 0.05%
cream, so most of the positive reactions to it must be due
Safety and Efficacy of Fluticasone
Propionate
Skin Pharmacol Physiol 2005;18:3–11 7
to cross-sensitivity. This observation is in line with an ear-
lier case report indicating allergy to FP as a cross-reaction
in a patient sensitive to many other topical corticosteroids
[43]. Therefore, in addition to the ‘classic’ goals of gluco-
corticoid research – high selectivity and low systemic
absorption – FP does not give rise to widespread corticoid
sensitization and might also be used in most patients who
have been previously sensitized to corticosteroids.
Treatment of AD with FP
Adults
Topical corticosteroids are the mainstay of therapy in
AD. In the previously mentioned study comparing FP
0.05% cream with hydrocortisone-17-butyrate 0.1%
cream, FP proved to be a both well-tolerated and effective
agent in the treatment of patients with moderate-to-severe
eczema [29]. Likewise, the 0.005% ointment formulation
revealed to be more effective than its vehicle [44] and sim-
ilar in efficacy to the high-potency drug betamethasone-
17,21-dipropionate 0.05% ointment [45] in the treatment
of mild-to-moderate eczema. After twice daily application
for 4 consecutive weeks, no significant differences in
terms of the physician’s gross assessment, the severity of
signs and symptoms of eczema and the patient’s assess-
ment of treatment effects were observed.
However, many clinicians are reluctant to prescribe
high-potency topical corticosteroids for the long-term
treatment of AD of the face and intertriginous areas
because these areas are more susceptible to corticosteroid
penetration due to thin skin and self-occlusion. The in
vitro use of FP 0.005% ointment on surgically excised
eyelid skin has already been reported to bear a low risk of
cutaneous side-effects and suggests that FP might be a
suitable candidate for the management of the face and
intertriginous areas [37]. Hence Tan et al. [46] conducted
a long-term open-label study of 21 adults with AD being
treated with FP 0.005% ointment twice daily for the first
2 weeks, and then only once daily for 2 consecutive days
each week for 8 more weeks. As a result, 95% of the per-
sons with facial and intertriginous lesions responded to
the treatment after 2 weeks. Furthermore, improvement
was maintained in most patients over a 71-day period,
patients had high remission rates of disease symptoms,
and there was no development of clinical signs of un-
wanted effects like skin atrophy or teleangiectasia [46].
Although this clinical trial did not assess eyelid or perior-
bital lesions, one might conclude that FP 0.005% oint-
ment is a safe and effective agent in the treatment of AD
on the face and intertriginous areas when tapering the
dose from a twice daily application to a long-term man-
agement regimen of once daily application on 2 consecu-
tive days every week for 8 weeks. At the same time, anoth-
er research group observed that pimecrolimus 1% cream,
a non-steroid inhibitor of inflammatory cytokines, might
be as efficacious and safer in the long-term treatment of
AD, thus reducing or eliminating the need for corticoste-
roid treatment [47]. However, these results do not point
towards a steroid-sparing effect of pimecrolimus as indi-
cated since the study does not refer to common therapeut-
ic standards as the topical corticosteroid is only applied in
the rare case of unacceptable itch and clinical signs like
crusting, excessive scratch marks or severe erythema.
After the use of the topical corticosteroid, patients had to
administer pimecrolimus or vehicle depending on the
group they were in, thus favouring the pimecrolimus
group which is treated with an active agent for 1 week
more than the placebo group. Furthermore, this study was
vehicle controlled, does not explicitly refer to the treat-
ment of sensitive areas such as facial and intertriginous
skin and administers prednicarbate 0.25% cream in the
event of flares. Therefore a clinical study comparing FP to
pimecrolimus in the long-term management of AD of the
face and intertriginous areas appears most interesting.
Children
Among the paediatric population, AD is the most com-
mon chronic disease in Europe, the USA and Japan. The
‘gold standard’ of therapy is a mildly or moderately potent
topical glucocorticosteroid such as hydrocortisone and
clobetasone butyrate, respectively, with emollients as ef-
fective adjuncts to achieve a steroid-sparing effect with-
out compromising the anti-inflammatory efficacy [48,
49]. An observational study compared FP 0.05% cream
(once daily) to clobetasone butyrate 0.05% cream (twice
daily) in 21 children (3–8 years old) with moderate AD
and showed that these two therapeutic regimens are both
safe with FP 0.05% cream being at least as effective as
clobetasone butyrate 0.05% cream [50].
An effective method of treatment with dressings in
children with AD is the wet-wrap technique involving the
use of open-weave cotton tubular dressings impregnated
with diluted topical corticosteroids [51]. A comparative
trial evaluated the efficacy of wet wraps using FP 0.005%
ointment and mometasone furoate 0.1% ointment for the
treatment of refractory AD in 27 children [52]. The agents
were allotted once daily for 4 weeks without wet wraps or
for 2 weeks without wet wraps followed by 2 weeks of
application under wet wraps. Interestingly, significant
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clinical improvement stagnated after 2 weeks in patients
who were solely treated with the open application, while
those with wet wraps continued to improve and finished
the study with significantly less severe disease [52]. The
low drop-out rate of 5.5% indicated that the wet wraps
were well tolerated. Therefore both, FP 0.005% and
mometasone furoate ointments, are effective in the treat-
ment of AD with wet wraps as an intermittent and short-
term measure being useful in further improving this skin
disorder. Since the wet-wrap technique represents an
occlusive and hydrating dressing on children with in-
flamed skin and a defective barrier, percutaneous absorp-
tion and systemic bioactivity of the corticosteroid might
be increased. In order to decrease the amount of topical
corticosteroid used, Wolkerstorfer et al. [53] evaluated the
efficacy and safety of several dilutions of FP 0.05% cream
(i.e. 5, 10, 25 and 50%) for 2 weeks. Most notably, the
significant clinical improvement in children with AD
was, irrespective of the FP dilution, applied under a wet
wrap and occurred mainly during the first week of treat-
ment. Taking into account that the second week of treat-
ment only led to minor improvements, the authors con-
cluded that 1 week of treatment with a 5% dilution under
a wet wrap might suffice to achieve major improvement
in the treatment of children with severe AD.
Maintenance Treatment in Adults and Children
AD is a chronic relapsing condition and requires a
long-term management approach since many patients will
experience recurrent exacerbations [54]. Prompt treat-
ment of flare-ups by twice daily administered topical mid-
strength corticosteroids until the inflammation subsides is
recommended by many dermatologists as first-line treat-
ment for the control of relapses, thus minimizing steroid
exposure and the risk of local or systemic side-effects [54].
Several recent studies have investigated a treatment ap-
proach to the long-term management of AD with FP. A
small-scale study indicated that once an acute flare-up of
AD had been stabilized by daily FP 0.005% ointment,
remission of AD can be maintained with regular daily use
of emollients and bath oil plus FP applied twice weekly to
areas of the skin that had been brought under control but
were prone to relapse [55]. By this treatment strategy, the
risk of relapse was reduced two- to threefold, and the
relapse-free period could be extended to more than 16
weeks, while the median time to relapse was just over
4 weeks in subjects receiving intermittent vehicle plus
emollients [55]. A large multicentre study comprising
both adult (44%) and paediatric (66%) subjects (aged 3
months up to 65 years) with moderate to severe AD also
gave evidence of marked clinical improvement of AD due
to FP 0.05% cream in terms of efficacy and safety [56]. By
administration of the cream formulation, the risk of
relapse was reduced sevenfold in adults and eightfold in
children. Furthermore, the relapse-free period on inter-
mittent FP/emollients was estimated to exceed 20 weeks,
while the median time to relapse was just 4–5 weeks in
subjects receiving intermittent vehicle plus emollients.
However, it remains puzzling that the cream formula-
tion is more effective than the more occlusive ointment
formulation found to be equipotent in the vasoconstric-
tion assay irrespective of the differing concentration [22].
Hence these two trials were followed by a similar large-
scale study only with adult patients (aged 12–65 years)
exploring the efficacy and safety of both, FP 0.05% cream
and 0.005% ointment, applied according to the same regi-
mens [57]. As a result, following stabilization of a flare,
the addition of regular, twice weekly FP to an emollient
maintenance regimen also significantly reduced the risk
of relapse in moderate to severe AD. However, FP 0.05%
cream again proved to be more effective than FP 0.005%
ointment with the risk of relapse being reduced sixfold
and twofold, respectively [57]. The authors conclude that
the potency of a topical corticosteroid preparation as
determined by the human vasoconstriction/skin blanch-
ing assay as an index of percutaneous absorption of a
compound might not fully reflect its performance in treat-
ing healed and active lesions of AD. Furthermore, from a
cosmetic point of view, ointments are greasy and patients
might feel less comfortable, which might have affected the
patients’ compliance with ointments. However, further
studies are warranted to fully elucidate the unexpected
difference between these formulations.
As already shown, most of the published data about the
long-term benefits of FP in the maintenance treatment of
AD focus on adults. Hence, two recent multicentre studies
compared the efficacy of FP 0.05% cream versus the
mildly potent hydrocortisone 1% cream and the moder-
ately potent hydrocortisone-17-butyrate 0.1% cream, re-
spectively, for both acute and maintenance treatment of
AD in children (aged 2–14 years) [58]. The respective
creams were allotted twice daily for 2–4 weeks until AD
was stabilized, and thereafter treatment was stepped
down intermittently as required (up to twice daily) to
affected areas at the first sign of a relapse for up to 12
weeks. Patients were also allowed to use emollients as
required. The total AD score combining measures of both
extent and severity of AD, the diary card data and the
final clinic visit of the maintenance phase indicated that
FP applied twice daily was significantly more effective in
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both the acute and long-term management of moderate
to severe AD than hydrocortisone or hydrocortisone-17-
butyrate. The treatment differences between FP 0.05%
cream and hydrocortisone-17-butyrate 0.1% cream differ
from the results of Juhlin [29], who reported no difference
between these agents. However, the recent observations
were solely made in paediatric patients and underscore
that FP provides a high level of efficacy and maintenance
of disease control with a tolerability similar to the mildly
potent hydrocortisone 1%.
Treatment of Psoriasis with FP
Several studies compared the efficacy of FP with other
agents in the treatment of psoriasis, a chronic, genetically
influenced, immune-mediated skin disease characterized
by abnormal proliferation and differentiation of epider-
mal keratinocytes as well as dermal infiltration of inflam-
matory components. Callen [59] discusses two double-
blind, randomized, parallel-group 4-week studies that
evaluated FP 0.05% cream versus betamethasone valer-
ate 0.1% cream, also a medium potent topical corticoste-
roid, in the treatment of moderate-to-severe psoriasis.
Concerning efficacy, no statistically significant differ-
ences could be found between the two agents. In a further
4-week study enrolling 125 patients with moderate-to-
severe psoriasis, FP 0.05% cream proved to be superior to
hydrocortisone-17-butyrate 0.1% cream after a duration
of 3 weeks and at the end-of-treatment visit. By the end of
therapy (i.e. 4 weeks), the skin of 79% of patients receiv-
ing FP 0.05% cream was rated as cleared, excellent or
good versus that of 68% of patients who used hydrocorti-
sone-17-butyrate 0.1% cream [60].
Nürnberger [61] describes a trial that compared twice
daily administration of FP 0.005% ointment with hydro-
cortisone-17-butyrate 0.1% ointment in 115 adults with
moderate-to-severe psoriasis. Most patients had psoriatic
involvement of long duration with an affected mean body
surface area of 17%. In this difficult-to-treat population,
FP was found to be therapeutically superior to hydrocorti-
sone-17-butyrate ointment. Fluticasone had a rapid onset
of action, significantly reduced psoriatic plaque scaling
and thickening after 1 week and erythema after 2 weeks of
treatment. Cleared, excellent or good end-of-treatment
response rates were 72% for FP compared with 68% for
hydrocortisone-17-butyrate. A comparison of the efficacy
between FP 0.005% ointment and a high-potency cortico-
steroid, betamethasone-17,21-dipropionate 0.05% oint-
ment, revealed no significant differences while both medi-
cations were well tolerated [62]. This finding is important,
since FP bears a lower risk for local and systemic side-
effects and might have excellent safety for treatment of
corticosteroid-responsive dermatoses, particularly those
of the recurring type such as psoriasis. Furthermore, the
use of FP has been associated with a low risk of cutaneous
side-effects for sensitive facial and intertriginous areas
[63]. FP 0.005% ointment was applied twice daily for 2
weeks of acute treatment, followed by a long-term man-
agement phase of 8 weeks, during which the dosage was
decreased to once daily for 2 consecutive days every week.
Most patients maintained improvement over 71 days of
the study, and no patient experienced clinical signs of
atrophy or teleangiectasia. Recurrence rates were low in
facial and intertriginous sites and significantly lower than
in non-facial, non-intertriginous areas [63].
Treatment of Vitiligo with FP
Vitiligo is an acquired skin disorder caused by the dis-
appearance of pigment cells from the epidermis. His-
tology shows a complete absence of melanocytes in the
lesions. Although there is no universally effective and safe
therapy available, many treatment options such as photo-
(chemo)therapy, autologous transplantation methods, de-
pigmentation therapy and corticosteroid use [64] have
been well established. It is assumed that corticosteroids
suppress inflammatory and auto-immune processes in
active progressing lesions, thus allowing melanocyte repo-
pulation spontaneously or by UV irradiation [64].
Novel strategies include a long-term combination ther-
apy of topical FP plus exposure to long-wave ultraviolet A
radiation (320–400 nm). FP 0.05% cream allotted once
daily and ultraviolet A irradiation (10 J/cm2) performed
twice weekly proved to be synergistic in repigmenting
localized vitiligo lesions [65]. The combination therapy
led to a better repigmentation than either treatment alone.
Perifollicular and marginal repigmentation could be ob-
served as fast as 6 weeks after the start of therapy in the
treated skin. After a period of 9 months, clinical and his-
tological examinations revealed no evidence of skin thin-
ning or teleangiectasia in both adult and paediatric pa-
tients and indicate that FP is a well-tolerated corticoste-
roid with high anti-inflammatory efficacy for the long-
term treatment of vitiligo.
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Conclusion
The numerous clinical applications of the topical mid-
potency corticosteroid FP for the treatment of AD, pso-
riasis and vitiligo have been described and attest to its
central role in dermatological practice. In addition, poten-
tial novel indications of FP corresponding to the benefi-
cial effect on skin barrier disruption caused by nickel-
induced allergic contact dermatitis come to horizon [66,
67]. Studies about FP are accumulating, and results sug-
gest an increased overall therapeutic potential in terms of
efficacy and tolerability due to its increased affinity and
improved GR pharmacokinetics.
Comparative trials indicate that this unique carbo-
thioate combines potent anti-inflammatory effects and a
low potential for unwanted systemic and local side-
effects: topical activity of FP judging from vasoconstric-
tion proved to be high [22], while skin thinning, allergenic
potential and hypothalamic-pituitary-adrenal inhibitory
potency are exceptionally weak. According to the guide-
lines of the German Dermatological Society (Deutsche
Dermatologische Gesellschaft) these parameters allow the
calculation of the therapeutic index as a useful marker of
quality to compare the most commonly prescribed topical
corticosteroids in Germany [68]. The value to be deter-
mined reaches 2.0, thus being the highest currently found.
While this would not indicate a difference to other topical
glucocorticoids with increased benefit-to-risk ratio, i.e.
prednicarbate, methylprednisolone aceponate and mom-
etasone furoate, FP so far looks unique when it comes to
its application in particularly steroid-sensitive areas as
well as in the maintenance treatment of relapse/prone
chronic inflammatory skin diseases such as AD and pso-
riasis vulgaris.
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